Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Galantamine hydrobromide

October 20, 2015

Non-proprietary name

Galantamine hydrobromide

Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reaction subsection of the Adverse reaction section, the following text should be added (underlined parts are revised):

Rhabdomyolysis:
Rhabdomyolysis may occur. Patients should be carefully monitored. If symptoms including myalgia, feelings of weakness, increased creatine kinase (creatine phosphokinase), or increased blood and urine myoglobin are observed, administration of this drug should be discontinued and appropriate measures should be adopted.

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp